

DESCRIPTION

Species Reactivity	Human
Specificity	Detects Human Galectin-9 in direct ELISA.
Source	Recombinant Monoclonal Rabbit IgG Clone # 2315B
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Human embryonic kidney cell, HEK293 derived human Galectin-9 Met1-Thr323 Accession # O00182
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Intracellular Staining by Flow Cytometry Titration recommended for optimal concentration with starting range of 0.1-1 µg/1 million cells. Sample used for this experiment was HEK293 cell line transfected with Galectin-9 vs irrelevant HEK293 transfectant cells.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Galectins comprise a family of multifunctional carbohydrate-binding proteins with specificity for N-acetyl-lactosamine-containing glycoproteins. At least 14 mammalian Galectins share structural similarities in their carbohydrate recognition domains (CRD), forming three groups: prototype (one CRD), tandem-repeat (two CRDs), and chimeric (one CRD, unique N-terminus) (1, 2). Full length Galectin-9 is a widely expressed 39 kDa tandem-repeat Galectin that contains two CRDs connected by a linker region (3). Progressive deletion within the linker region generates a 36 kDa isoform, also known as Ecalectin or UAT, as well as a 35 kDa isoform (4). This recombinant protein corresponds to the Ecalectin isoform of human Galectin-9 and shares 70% and 73% aa sequence identity with the corresponding regions of mouse and rat Galectin-9, respectively. Galectin-9 exhibits a wide range of activities. All three isoforms function as eosinophil chemoattractants (5, 6). This activity is destroyed by thrombin-mediated cleavage within the linker region of the long isoform, although the Ecalectin isoform is resistant to thrombin (7). Galectin-9 binds to carbohydrate moieties of IgE, thereby preventing immune complex formation, mast cell degranulation, and asthmatic and cutaneous anaphylaxis reactions (8). Independent of its lectin properties, Galectin-9 induces the maturation of dendritic cells which promote Th1 polarization (9). Galectin-9 induces cellular apoptosis in part by direct binding to TIM-3 (10, 11). Its interaction with TIM-3 inhibits Th1 cell and CD8⁺ cytotoxic T cell responses and also promotes regulatory T cell differentiation and activity (11, 12). Galectin-9 suppresses tumor cell metastasis by interfering with the associations between hyaluronic acid and CD44 and between VCAM-1 and Integrin α4β1 (13). The Ecalectin isoform (UAT; urate transporter) can also be expressed as an integral membrane protein and mediate the cellular efflux of urate (14).

References:

1. Heusschen, R. *et al.* (2013) *Biochim. Biophys. Acta* **1836**:177.
2. Elola, M. T. *et al.* (2007) *Cell. Mol. Life Sci.* **64**:1679.
3. Tureci, O. *et al.* (1997) *J. Biol. Chem.* **272**:6416.
4. Chabot, S. *et al.* (2002) *Glycobiology* **12**:111.
5. Matsumoto, R. *et al.* (2002) *J. Immunol.* **168**:1961.
6. Sato, M. *et al.* (2002) *Glycobiology* **12**:191.
7. Nishi, N. *et al.* (2006) *Glycobiology* **16**:15C.
8. Niki, T. *et al.* (2009) *J. Biol. Chem.* **284**:32344.
9. Dai, S.-Y. *et al.* (2005) *J. Immunol.* **175**:2974.
10. Seki, M. *et al.* (2007) *Arthritis Rheum.* **56**:3968.
11. Zhu, C. *et al.* (2005) *Nat. Immunol.* **6**:1245.
12. Sehrawat, S. *et al.* (2010) *PloS Pathogens* **6**:e1000882.
13. Nobumoto, A. *et al.* (2008) *Glycobiology* **18**:735.
14. Leal-Pinto, E. *et al.* (2002) *Am. J. Physiol. Renal Physiol.* **283**:F150.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.